Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181


Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML.

Sallmyr A, Fan J, Datta K, Kim KT, Grosu D, Shapiro P, Small D, Rassool F.

Blood. 2008 Mar 15;111(6):3173-82. doi: 10.1182/blood-2007-05-092510. Epub 2008 Jan 11.


The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.

Grundy M, Seedhouse C, Shang S, Richardson J, Russell N, Pallis M.

Mol Cancer Ther. 2010 Mar;9(3):661-72. doi: 10.1158/1535-7163.MCT-09-1144. Epub 2010 Feb 16.


Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.

Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, Grüning W, Kratz-Albers K, Serve S, Steur C, Büchner T, Kienast J, Kanakura Y, Berdel WE, Serve H.

Blood. 2000 Dec 1;96(12):3907-14.


NADPH oxidase-generated hydrogen peroxide induces DNA damage in mutant FLT3-expressing leukemia cells.

Stanicka J, Russell EG, Woolley JF, Cotter TG.

J Biol Chem. 2015 Apr 10;290(15):9348-61. doi: 10.1074/jbc.M113.510495. Epub 2015 Feb 19.


FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.

Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, Iino T, Rocnik JL, Kikushige Y, Mori Y, Shima T, Iwasaki H, Takenaka K, Nagafuji K, Mizuno S, Niiro H, Gilliland GD, Akashi K.

Blood. 2009 Dec 3;114(24):5034-43. doi: 10.1182/blood-2008-12-196055. Epub 2009 Oct 6.


SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.

Leischner H, Albers C, Grundler R, Razumovskaya E, Spiekermann K, Bohlander S, Rönnstrand L, Götze K, Peschel C, Duyster J.

Blood. 2012 Apr 26;119(17):4026-33. doi: 10.1182/blood-2011-07-365726. Epub 2012 Mar 12.


Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).

Murata K, Kumagai H, Kawashima T, Tamitsu K, Irie M, Nakajima H, Suzu S, Shibuya M, Kamihira S, Nosaka T, Asano S, Kitamura T.

J Biol Chem. 2003 Aug 29;278(35):32892-8. Epub 2003 Jun 18.


FLT3-ITD expression levels and their effect on STAT5 in AML with and without NPM mutations.

Seedhouse CH, Pallis M, Grundy M, Shang S, Russell NH.

Br J Haematol. 2009 Dec;147(5):653-61. doi: 10.1111/j.1365-2141.2009.07901.x. Epub 2009 Sep 22.


Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.

Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A, Kiyoi H, Towatari M, Naoe T.

Leukemia. 2007 Mar;21(3):403-10. Epub 2007 Jan 18.


Activation mechanisms of STAT5 by oncogenic Flt3-ITD.

Choudhary C, Brandts C, Schwable J, Tickenbrock L, Sargin B, Ueker A, Böhmer FD, Berdel WE, Müller-Tidow C, Serve H.

Blood. 2007 Jul 1;110(1):370-4. Epub 2007 Mar 13.


Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair.

Sallmyr A, Fan J, Rassool FV.

Cancer Lett. 2008 Oct 18;270(1):1-9. doi: 10.1016/j.canlet.2008.03.036. Epub 2008 May 7. Review.


Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ.

Godfrey R, Arora D, Bauer R, Stopp S, Müller JP, Heinrich T, Böhmer SA, Dagnell M, Schnetzke U, Scholl S, Östman A, Böhmer FD.

Blood. 2012 May 10;119(19):4499-511. doi: 10.1182/blood-2011-02-336446. Epub 2012 Mar 20.


Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction.

Tickenbrock L, Schwäble J, Wiedehage M, Steffen B, Sargin B, Choudhary C, Brandts C, Berdel WE, Müller-Tidow C, Serve H.

Blood. 2005 May 1;105(9):3699-706. Epub 2005 Jan 13.


H2O2 production downstream of FLT3 is mediated by p22phox in the endoplasmic reticulum and is required for STAT5 signalling.

Woolley JF, Naughton R, Stanicka J, Gough DR, Bhatt L, Dickinson BC, Chang CJ, Cotter TG.

PLoS One. 2012;7(7):e34050. doi: 10.1371/journal.pone.0034050. Epub 2012 Jul 13.


Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.

Pietschmann K, Bolck HA, Buchwald M, Spielberg S, Polzer H, Spiekermann K, Bug G, Heinzel T, Böhmer FD, Krämer OH.

Mol Cancer Ther. 2012 Nov;11(11):2373-83. doi: 10.1158/1535-7163.MCT-12-0129. Epub 2012 Aug 31.


FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia.

Kazi JU, Rönnstrand L.

Mol Oncol. 2013 Jun;7(3):402-18. doi: 10.1016/j.molonc.2012.11.003. Epub 2012 Nov 29.


Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.

Shih LY, Lin TL, Wang PN, Wu JH, Dunn P, Kuo MC, Huang CF.

Cancer. 2004 Sep 1;101(5):989-98.


NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.

Gerloff D, Grundler R, Wurm AA, Bräuer-Hartmann D, Katzerke C, Hartmann JU, Madan V, Müller-Tidow C, Duyster J, Tenen DG, Niederwieser D, Behre G.

Leukemia. 2015 Mar;29(3):535-47. doi: 10.1038/leu.2014.231. Epub 2014 Aug 5.


Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.

J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29.


Risk assessment in patients with acute myeloid leukemia and a normal karyotype.

Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.

Clin Cancer Res. 2005 Feb 15;11(4):1416-24. Erratum in: Clin Cancer Res. 2005 Aug 1;11(15):5659.

Items per page

Supplemental Content

Write to the Help Desk